TG4050
One patient, one cancer, one vaccine
TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities.
TG4050 is being evaluated in a Phase I/II clinical trial.
